Cilastazol is a 2-oxo-quinoline with vasodilator, antimitogenic, antithrombotic, and cardiotonic properties. This compound has been shown to cause inhibition of adenosine uptake, eventually resulting in changes to cAMP levels. Studies have shown Cilostazol to be a potent inhibitor of PDE3A (phosphodiesterase 3A) in vitro. PDE3A is often in the Cardiac system. In addition Cilastazol has also been observed to inhibit mitogenesis, migration of vascular smooth muscle cells, and platelet aggregation in vitro. Cilostazol displays a capacity to lower levels of serum triglycerides and cause some increase in HDL-cholesterol levels in vitro.
1. Schrör, K. 2002. Diabetes Obes Metab. 4: S14-S19. PMID: 12180353
2. Kambayashi, J., et al. 2003. Curr. Pharm. Des. 9: 2289-2302. PMID: 14529391
3. Lee, J.H., et al. 2004. J. Pharmacol. Exp. Ther. 308: 896-903. PMID: 14634032
4. Lee, J.H., et al. 2008. CNS Neurosci Ther. 14: 143-152. PMID: 18482026
See how others have used Cilostazol. Click on the entry to view the PubMed entry .
PMID: # 25843350 Kim, T. et al. 2015. Metab. Eng. 29: 169-79.
PMID: # 15908466 Matsumoto, T. et al. 2005. Am. J. Physiol. Heart Circ. Physiol. 289: H1933-H1940.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.